Fig. 2From: Docking and ADMET studies for investigating the anticancer potency of Moscatilin on APC10/DOC1 and PKM2 against five clinical drugsLigands docked with target protein PKM2 (1ZJH), generated using PLIP. The ligands used were a Moscatilin, b Resveratrol, c Mitomycin-C, d Colchicine, e Paclitaxel, and f ShikoninBack to article page